Online supplemental material

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

Takashi Kojima¹, Hiroki Harab, Akihito Tsuji², Hisateru Yasui³, Kei Muro⁴, Taroh Satoh⁵, Takashi Ogata⁶, Ryu Ishihara⁷, Masahiro Goto⁸, Hideo Baba⁹, Tomohiro Nishina⁵, Shirong Han¹, Tomoko Sakata¹, Naoyoshi Yatsuzuka¹, Toshihiko Doi¹⁰, Ken Kato¹

¹Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan; ²Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan; ³Department of Medical Oncology, Kagawa University Hospital, Kagawa, Japan; ⁴Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan; ⁵Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan; ⁶Department of Frontier Science for Cancer and Chemotherapy, Osaka University Hospital, Osaka, Japan; ⁷Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan; ⁸Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan; ⁹Division of Medicine, Osaka Medical College Hospital, Osaka, Japan; ¹⁰Department of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto, Japan; ¹¹Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan; ¹²Department of Medical Oncology, MSD K.K., Tokyo, Japan; ¹³Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan; ¹⁴Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Esophagus

Corresponding Author
Ken Kato, MD, PhD
National Cancer Center Hospital
5-1-1, Tsukiji, Chuo-ku
Tokyo, 104-0045, Japan
Phone: 03-3542-2511 (7902)
Fax: 03-3452-3815
Email: kenkato@ncc.go.jp
Online Resource 1. CONSORT diagram.
| Therapy, n (%)                  | Pembrolizumab + chemotherapy |
|--------------------------------|-------------------------------|
|                                | \( n = 64^a \)                | Chemotherapy \( n = 65^a \) |
| All patients                   | 44 (68.8)                     | 49 (75.4)                  |
| **Incidence ≥5% in any treatment group** |                              |                            |
| Cisplatin                      | 11 (17.2)                     | 12 (18.4)                  |
| Docetaxel                      | 5 (7.8)                       | 8 (12.3)                   |
| Fluorouracil                   | 20 (31.3)                     | 14 (21.5)                  |
| Oxaliplatin                    | 10 (15.6)                     | 2 (3.1)                    |
| Paclitaxel                     | 31 (48.4)                     | 36 (55.4)                  |
| Ramucirumab                    | 5 (7.8)                       | 4 (6.2)                    |
| **Immunotherapy incidence ≥0%** |                              |                            |
| Anti–LAG-3 mAb                 | 0 (0)                         | 1 (1.5)                    |
| Anti–PD-1 mAb                  | 0 (0)                         | 1 (1.5)                    |
| Nivolumab                      | 5 (7.8)                       | 11 (16.9)                  |
| Pembrolizumab                  | 2 (3.1)                       | 0 (0)                      |

\(^a\)Number of patients who discontinued study medication.